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Introduction
Trastuzumab (Herceptin ® , F. Hoffmann-La Roche Ltd, Basel, Switzerland), is the standard of care for treating human epidermal growth factor receptor 2 (HER2)-positive breast cancer [1] [2] [3] and can be administered by intravenous (IV) infusion or subcutaneous (SC) injection. SC trastuzumab (Herceptin ® SC, F. Hoffmann-La Roche Ltd) contains the recombinant human hyaluronidase enzyme as an excipient and offers a fixed-dose alternative to the conventional weight-adjusted IV dose. SC trastuzumab was approved by the European Medicines Agency based on data from the phase III, open-label, randomised, international HannaH study (NCT00950300) [4, 5] .
HannaH compared SC and IV trastuzumab in terms of pharmacokinetics, efficacy and safety in the neoadjuvant-adjuvant setting [4, 5] . Analysis of the co-primary endpoints, serum trough concentration (Ctrough) and pathological complete response (pCR), demonstrated that SC trastuzumab was noninferior to IV [4] . Despite similar overall safety profiles, a numerical difference was reported in the rate of serious adverse events (SAEs) [4, 5] . This imbalance was not reflected in the distribution of grade 3-5 AEs, and despite systematic analyses an underlying clinical explanation could not be identified [4, 5] . An SC trastuzumab single-use injection device (SID) demonstrates pharmacokinetic bioequivalence with the hand-held syringe method [6] .
Patients' preferences, for either SC administration or IV infusion, were investigated in the international, open-label, randomised, two-cohort, two-arm, PrefHer study (NCT01401166) in HER2-positive early breast cancer [7] [8] [9] .
PrefHer incorporated a unique crossover period, comprising four cycles of SC 6 trastuzumab followed by four cycles of IV, or vice versa. This study design allowed a direct comparison of patients' preferences for SC or IV trastuzumab and evaluation of the safety profile associated with multiple, sequential administrations.
When compared with the known safety profile of IV trastuzumab, previous analyses from both cohorts of PrefHer indicated that SC trastuzumab was well tolerated, with no new safety signals [7] [8] [9] . Although an increase in clinicianreported AEs was noted with SC trastuzumab, this was not the case for patient-reported events [7, 9] . Differences between AE rates in the combined SC and IV periods (Cohorts 1 and 2) were driven by grade 1 events and occurred more frequently during the SC period [7, 9] . However, patients preferred SC over IV trastuzumab regardless of SID or hand-held syringe delivery, and patients reported SC trastuzumab to be less painful and to cause less bother from bruising or irritation than IV [7] [8] [9] .
With consistent patient preference for SC over IV trastuzumab and the European approval of SC trastuzumab, patients may opt to switch from IV to SC trastuzumab during their treatment for early breast cancer. Due to its unique design, the PrefHer study offered the opportunity to assess the safety profile of patients switching between IV and SC trastuzumab, considering not only the influence of the treatment sequence, but also the impact of previous exposure to IV trastuzumab during (neo)adjuvant treatment. We report the results of this analysis here.
Patients and methods

Patients and study treatment
After completion of surgery and neoadjuvant or adjuvant chemotherapy, patients were randomised to receive four cycles of SC trastuzumab followed by four cycles of IV trastuzumab, or vice versa (the crossover period assessed here; Fig. 1 ) [7] [8] [9] . Patients then received trastuzumab to complete their standard 18 cycles of adjuvant treatment, planned to be via IV or SC SID in Cohort 1 and SC hand-held syringe in Cohort 2. Since (neo)adjuvant treatment could have included prior IV trastuzumab, randomisation was stratified by de novo (trastuzumab-naïve) or non-de novo (already receiving IV trastuzumab) treatment. Patients were enrolled if they still had at least eight out of their 18 planned cycles of trastuzumab remaining.
SC trastuzumab was administered either via SID (Cohort 1) or hand-held syringe (Cohort 2) and given every 3 weeks at a fixed dose of 600 mg, with no loading dose required. IV trastuzumab was administered every 3 weeks at a loading dose of 8 mg/kg (if the patient was not already receiving trastuzumab and was randomised to receive IV trastuzumab as the first cycle of treatment), followed by maintenance doses of 6 mg/kg.
The primary endpoint, previously reported, was the proportion of patients indicating an overall preference for SC or IV trastuzumab administration [7, 9] .
Secondary endpoints included safety and tolerability [7] [8] [9] . 8 PrefHer was conducted in accordance with Good Clinical Practice guidelines and the Declaration of Helsinki. All patients provided written informed consent.
Approval for the protocol was obtained from appropriate local and national independent ethics committees.
Assessment of switching between SC and IV trastuzumab
AEs that occurred during the crossover period were summarised according to the primary system-organ class (SOC), and within each SOC by Medical AEs and patients' preferences were compared in the evaluable intention-totreat (ITT) population (patients who completed both interviews and had ≥1 administration of both SC and IV trastuzumab).
Results
Patients
Baseline patient demographics, tumour characteristics and treatment histories of patients enrolled in Cohorts 1 and 2 of PrefHer have been reported previously [7] [8] [9] . A total of 488 patients (Cohorts 1 and 2 pooled), from 12 countries and 74 sites, participated, and the evaluable ITT population included 235 patients randomised to receive SC followed by IV (SC→IV arm), and 232 to receive IV followed by SC (IV→SC arm) ( Fig. 2 ) [7] [8] [9] . The safety population comprised 483 patients (five randomised patients did not receive study treatment); most patients (459/483 [95.0%]) completed all eight cycles [7] [8] [9] . Of the safety population patients, 243 were randomised to receive four cycles of SC→IV trastuzumab, and 240 patients the alternate sequence. Of these, 242 patients were treated with SC trastuzumab using the SID and 237 using the hand-held syringe; 24 patients completed <8 cycles during the crossover period [9] . The majority of patients had prior trastuzumab treatment 
Safety analysis during the crossover period (pooled cohorts)
Overall, the safety profiles of the pooled cohorts were similar between SC and IV trastuzumab during the crossover period, with no new safety signals observed ( Table 1 ) [7] [8] [9] .
Within the SC→IV arm, the rate of AEs during SC treatment was 65.4%
(159/243 patients), compared with 48.7% during IV treatment (116/238 patients). The incidence of grade ≥3 AEs was 4.5% (11/243 patients) during 11 SC treatment and 2.9% (7/238 patients) during IV treatment. While there were a number of SOCs that were reported more frequently during SC administration (Table 2) Overall, the majority of ARRs were grade 1 or 2 and the frequency of grade 3
ARRs in both treatment arms was low (<2% in the SC→IV arm and <1% in the IV→SC arm). ISRs were observed exclusively during the SC periods in both treatment arms, except in one patient in the IV→SC arm who experienced an ISR during IV treatment ( Table 1) .
The proportion of patients experiencing a clinically important event, including grade ≥3 AEs, SAEs, AEs leading to study drug discontinuation or cardiac AEs, was similar between treatment groups (Table 1) . Overall, eight patients reported nine SAEs during the SC or IV treatment periods (four patients during the SC treatment periods and four during the IV treatment periods; Table 1 ) and 11 patients withdrew from treatment due to AEs (five during the SC treatment periods and six during the IV treatment periods; Differences in AE rates by grade between the SC and IV periods were observed only for grade 1 and 2 AEs (Fig. 3) . Grade 3 AEs were reported for 17 patients (7.0%) in the SC→IV treatment arm (11 [4.5%] (Fig. 3 ) [7] [8] [9] .
Safety analysis during the crossover period (individual cohorts)
Comparison of the SID and hand-held syringe methods of administering SC trastuzumab revealed a similar pattern of clinically important AEs to the overall analysis (Tables 3 and 4) . No new safety signals specific to either method were observed.
AE rates in patients de novo or non-de novo for trastuzumab treatment (pooled cohorts)
The majority of patients (n = 385) received prior trastuzumab. Although the number of prior cycles varied (1-10), AE rates, excluding ISRs and ARRs for patients in each treatment arm, whether de novo or non-de novo for trastuzumab treatment, were higher during the first treatment period compared with the second, regardless of whether patients received SC or IV trastuzumab ( Table 5) . 13 In the IV→SC arm, AEs rates were similar between the IV and SC treatment periods for de novo and non-de novo patients. Patients in the non-de novo group reported a higher proportion of AEs for all AE categories compared with de novo patients.
Relationship between patients' preference and safety
There was no clear link between grade 3 and grade 1-2 AEs and patients' preferences for SC or IV trastuzumab (Supplementary Table 1 ). As previously reported, patients overwhelmingly preferred SC administration of trastuzumab [7] [8] [9] .
Discussion
Trastuzumab has improved the prognosis of patients with HER2-positive breast cancer in both early and metastatic disease [12, 13] . One year of trastuzumab is the standard of care in the adjuvant setting, providing consistent improvements in disease-free and overall survival [14, 15] . The
HannaH study compared SC and IV trastuzumab and reported that SC was non-inferior to IV in terms of pCR and Ctrough; safety was similar [4, 5] .
Previously published PrefHer analyses found that SC trastuzumab was well tolerated and that patients preferred it over IV administration [7] [8] [9] . The SafeHer study (NCT01566721) showed consistent safety results with the hand-held syringe; SID data are anticipated [16] .
Overall, the results from PrefHer's crossover period demonstrated a consistent safety profile with the known safety profile of IV trastuzumab [17] .
This analysis revealed no clinically relevant differences when patients switched between trastuzumab routes. While fewer AEs were reported during the IV treatment periods regardless of sequence (IV→SC or SC→IV), when ISRs and ARRs were excluded the rate of AEs was higher during the first period, compared with the second, in both treatment arms. Importantly, when switching from IV→SC, the frequency of clinically important events (grade ≥3 AEs, SAEs, AEs leading to trial drug discontinuation and cardiac AEs) was <5% and similar between treatment arms. Differences in grade 1 and 2 AEs between the SC and IV periods were partly due to variances in ISRs and ARRs. These occurred mainly during SC treatment, as expected; otherwise, there was no clear pattern in the types of AEs reported.
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The higher proportion of overall AEs in the non-de novo group could be explained by imbalanced subgroup sizes (de novo patients comprised 20% of the population). Also, considering that there were more AEs at the injection site with SC trastuzumab, particularly at the initiation of treatment, it is logical that these AEs are more marked during SC→IV treatment. Regardless, the important elements are that grade ≥3 AE rates were balanced, and that patients expressed a preference for SC trastuzumab regardless of whether they had received prior trastuzumab treatment [9] . As such, the difference in AE rates between de novo and non-de novo groups has no clinical impact.
Combining the SC SID and hand-held syringe cohorts for the switching analysis was considered appropriate as the SID is pharmacokinetically bioequivalent to the hand-held syringe [6] . AE profiles for the individual cohorts were generally similar to those observed for the pooled cohorts.
Previously reported analyses from PrefHer demonstrated that patients preferred SC trastuzumab, regardless of SID or hand-held syringe delivery [7] [8] [9] . The current analysis did not find any clear differences in AE profiles between the SID and the hand-held syringe.
This analysis was a safety review of the crossover period of PrefHer (four cycles of SC and four cycles of IV trastuzumab), and therefore does not take into consideration the overall safety profile. Following the crossover period, patients completed their remaining trastuzumab treatment (up to 18 cycles), and therefore AEs that may emerge with late onset are not reported.
Where several formulations may be available for the same drug, patient experience and preference may significantly affect treatment adherence and quality of life [18] . Patient preference is particularly pertinent when considering IV versus SC administration [18] . Among trials that compared IV and SC routes of administration of the same drug, only two had patient preference as the primary objective: PrefHer [7] [8] [9] and SWITCH [19] . The SWITCH trial compared elective switching (IV→SC) between two anti-tumour necrosis factor treatments, adalimumab and infliximab, in Crohn's disease [19] .
Overall, a clear preference for SC treatment was reported by patients in both studies [7] [8] [9] 19] . European approval of SC trastuzumab, in combination with overwhelming patient preference, suggests that patients may opt to switch from IV to SC trastuzumab in early breast cancer. The results of this analysis demonstrate that AE rates were similar when switching from IV to SC trastuzumab, with no new safety concerns.
In conclusion, during the crossover period, the PrefHer study demonstrated no clinically relevant safety differences when patients switched from IV to SC trastuzumab, or vice versa. PrefHer is the only study to provide prospective data on switching from IV→SC treatment and the data from this trial support switching in clinical practice. If an AE start date was partially or fully missing, and it was unclear during which treatment period the AE started, the AE was assigned to all relevant treatment periods.
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Abbreviations: AE, adverse event; ARR, administration-related reaction; ISR, injection site reaction; IV, intravenous; SAE, serious adverse event; SC, subcutaneous. Table 2 Adverse events by SOC and specific adverse event in ≥5% of patients (any group) when switching between trastuzumab administration routes during the crossover period (pooled cohorts; safety population) 
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complications All AEs, including SAEs, were included. If an AE start date was partially or fully missing, and it was unclear during which treatment period the AE started, the AE was assigned to all relevant treatment periods.
Abbreviations: AE, adverse event; IV, intravenous; SAE, serious adverse event; SC, subcutaneous; SOC, system-organ class. If an AE start date was partially or fully missing, and it was unclear during which treatment period the AE started, the AE was assigned to all relevant treatment periods.
Abbreviations: AE, adverse event; ARR, administration-related reaction; ISR, injection site reaction; IV, intravenous; SAE, serious adverse event; SC, subcutaneous; SID, single-use injection device. If an AE start date was partially or fully missing, and it was unclear during which treatment period the AE started, the AE was assigned to all relevant treatment periods.
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Abbreviations: AE, adverse event; ARR, administration-related reaction; HHS, hand-held syringe; ISR, injection site reaction; IV, intravenous; SAE, serious adverse event; SC, subcutaneous.
32 Table 5 Adverse events in patients de novo or non-de novo for trastuzumab administration prior to the crossover period (pooled cohorts; safety population) If an AE start date was partially or fully missing, and it was unclear during which treatment period the AE started, the AE was assigned to all relevant treatment periods.
Abbreviations: AE, adverse event; ARR, administration-related reaction; ISR, injection site reaction; IV, intravenous; SAE, serious adverse event; SC, subcutaneous.
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Appendix A. Supplementary data Abbreviations: AE, adverse event; IV, intravenous; ITT, intention-to-treat; SC, subcutaneous.
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